It was found that in patients with advanced HNSCC, treatment with orally administered escalating doses of 20, 40, and 60 μg of calcidiol significantly reduced levels of CD34-positive immune cells in the circulating blood while increasing the immune reactivity of peripheral blood T cells. This evidence concerns the gene CD34 and head and neck squamous cell carcinoma.